All AbMole products are for research use only, cannot be used for human consumption.
Rabusertib (LY2603618) is an effective and selective Chk1 inhibitor with an IC50 of 7 nM.
Invest New Drugs. 2025 Jan 27.
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer
Rabusertib (LY2603618) purchased from AbMole
 |
Source | Oncotarget (2017). Figure 2. LY2603618 |
| Method | Clonogenic survival | |
| Cell Lines | U2OS cells | |
| Concentrations | 0, 25, 50 or 100 nM | |
| Incubation Time | 24 hours | |
| Results | An exposure time of 24 hours to the inhibitors was chosen for the clonogenic survival assays to resemble a transient delivery of such inhibitors upon in vivo single injections. |
| Molecular Weight | 436.3 |
| Formula | C18H22BrN5O3 |
| CAS Number | 911222-45-2 |
| Solubility (25°C) | DMSO 12 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Checkpoint Products |
|---|
| PV-1019
PV-1019 (NSC 744039) is a potent, selective Chk2 inhibitor with an IC50 value of 24 nM. PV-1019 inhibits IR-induced apoptosis. |
| CCT241533 dihydrochloride
CCT241533 dihydrochloride is a potent and selective ATP competitive inhibitor of CHK2 with an IC50 of 3 nM and Ki of 1.16 nM. |
| CBP501 Affinity Peptide
CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents. |
| Chktide
Chktide is a substrate for CHK1 and CHK2. |
| Zn-DPA-maytansinoid conjugate 1
Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
